Sign up to save your podcasts
Or
Share James Peyer, Founder @ Cambrian
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
James Peyer, Founder @ Cambrian
In this episode, Jack Richardson and Richard Armstrong engage with James Pyre to explore the biotech landscape, delving into his background and the founding of Cambrian. The discussion highlights Cambrian's mission to tackle aging biology and compares biotech to tech investment landscapes. James shares insights into Cambrian's early funding, metabolism research, and drug development efforts. The conversation navigates the complexities of the regulatory environment and data management, emphasizing strategies to accelerate drug development and the future of longevity drugs. The episode wraps up with a quick-fire round of questions with James Pyre, followed by closing remarks.
James Peyer is the CEO and founder of Cambrian Bio, a company that develops therapeutics targeting key biological pathways that decline or malfunction with age to create medicines that have the potential to treat and prevent some of today's most debilitating diseases.
Cambrian is viewed as one of the most exciting biotech companies around, raising $160m in the last 5 years.
Brought to you by TAV, James joins Jack and Rich to discuss his personal journey, longevity, Cambrian's journey to human trials, regulatory considerations and so much more.
(0:00) Introduction and James Pyre's background in biotech
(3:16) The founding of Cambrian and tackling aging biology
(10:10) Comparing biotech to tech investment landscapes
(12:29) Cambrian's early funding and mission
(18:00) Metabolism research and drug development at Cambrian
(24:11) Navigating the regulatory environment and data management
(29:42) Accelerating drug development and the future of longevity drugs
(34:25) Quick fire questions with James Pyre
(37:41) Wrap-up and closing remarks
View all episodes
By Richard Armstrong, Jack RichardsonIn this episode, Jack Richardson and Richard Armstrong engage with James Pyre to explore the biotech landscape, delving into his background and the founding of Cambrian. The discussion highlights Cambrian's mission to tackle aging biology and compares biotech to tech investment landscapes. James shares insights into Cambrian's early funding, metabolism research, and drug development efforts. The conversation navigates the complexities of the regulatory environment and data management, emphasizing strategies to accelerate drug development and the future of longevity drugs. The episode wraps up with a quick-fire round of questions with James Pyre, followed by closing remarks.
James Peyer is the CEO and founder of Cambrian Bio, a company that develops therapeutics targeting key biological pathways that decline or malfunction with age to create medicines that have the potential to treat and prevent some of today's most debilitating diseases.
Cambrian is viewed as one of the most exciting biotech companies around, raising $160m in the last 5 years.
Brought to you by TAV, James joins Jack and Rich to discuss his personal journey, longevity, Cambrian's journey to human trials, regulatory considerations and so much more.
(0:00) Introduction and James Pyre's background in biotech
(3:16) The founding of Cambrian and tackling aging biology
(10:10) Comparing biotech to tech investment landscapes
(12:29) Cambrian's early funding and mission
(18:00) Metabolism research and drug development at Cambrian
(24:11) Navigating the regulatory environment and data management
(29:42) Accelerating drug development and the future of longevity drugs
(34:25) Quick fire questions with James Pyre
(37:41) Wrap-up and closing remarks